Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation
Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation
The purpose of this study is to determine whether MSCs are safe and effective in reducing the
 primary nonfunction (PNF), acute rejection and Ischemic-type Biliary Lesions (ITBLs)
 morbidity in ABO-incompatible Liver Transplantation.
ABO incompatible liver transplantations is considered to be a rescue option in emergency
 transplantation.The A、B antibodies to grafts bind to the graft endothelium and activate
 complement, which attracts and activates neutrophils and platelets and increases the
 permeability of the endothelium. The neutrophils exude, the platelets aggregate, and the
 small vessels of the graft get thrombosed, resulting in ischemic damage,leading nonfunction
 grafts.In addition, if the A、 B antibodies remain high level, it can lead to acute humoral
 immune rejection. A lot of research confirmed that the ABO incompatible is a risk factor of
 postoperative short- and long-term survival. And mesenchymal stromal cells (MSCs) are
 characterized by the properties of immunosuppressive and regenerative properties, which make
 MSCs great attractive in treating immunological diseases (including transplant rejection) and
 organ/tissue ischemic injury. So we conduct this clinical study,to confirm the effect of MSCs
 in ABO incompatible liver transplantation by comparing the incidence of primary nonfunction,
 acute rejection, biliary complications and survival rates.
Inclusion Criteria:

 -  First liver transplantation with a ABO-incompatible
 graft(B→A，AB→A，A→B，AB→B，A→O，B→O，AB→O).

 -  Ages of 18 or older.

 -  Patients receive liver transplantation due to benign end stage liver disease.

 -  Patients or legal agent must be able to give informed consent.

 Exclusion Criteria:

 -  Second or combined organ transplant recipient.

 -  Combined transplantations such as simultaneous liver/kidney transplants

 -  Malignant disease.

 -  Uncontrol bacterial, fungal, viral or parasitic infection.

 -  Withdraw or unable to finish the follow-up.

 -  Unwilling to sign informed consent.